Literature DB >> 31343354

The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril composition.

Jonas Wixner1, Per Westermark2, Elisabet Ihse2, Björn Pilebro1, Hans-Erik Lundgren1, Intissar Anan1.   

Abstract

Entities:  

Year:  2019        PMID： 31343354     DOI： 10.1080/13506129.2019.1593133

Source DB:  PubMed          Journal:  Amyloid        ISSN： 1350-6129            Impact factor:   7.141


× No keyword cloud information.
  4 in total

1.  Preparative Scale Production of Recombinant Human Transthyretin for Biophysical Studies of Protein-Ligand and Protein-Protein Interactions.

Authors:  Ellen Y Cotrina; Marta Vilà; Joan Nieto; Gemma Arsequell; Antoni Planas
Journal:  Int J Mol Sci       Date:  2020-12-17       Impact factor: 5.923

Review 2.  Cardiac Amyloidosis Treatment.

Authors:  Lily K Stern; Jignesh Patel
Journal:  Methodist Debakey Cardiovasc J       Date:  2022-03-14

Review 3.  Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges.

Authors:  Carsten Tschöpe; Ahmed Elsanhoury
Journal:  J Clin Med       Date:  2022-04-12       Impact factor: 4.964

4.  Specific Therapy for Transthyretin Cardiac Amyloidosis: A Systematic Literature Review and Evidence-Based Recommendations.

Authors:  Nuno Marques; Olga Azevedo; Ana Rita Almeida; Dina Bento; Inês Cruz; Emanuel Correia; Carolina Lourenço; Luís Rocha Lopes
Journal:  J Am Heart Assoc       Date:  2020-09-24       Impact factor: 5.501
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.